BRAF and melanoma: Dabrafenib was also a selective inhibitor of BRAF kinase for patients suffering from BRAF-mutated melanoma, advanced non-small cell lung cancer, and anaplastic thyroid cancer harboring the BRAFV600E mutation (Puszkiel et al., 2019).